HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion

Eli Lilly's Omvoh showed a 50% clinical remission rate in paediatric UC patients in the SHINE-2 study, meeting its primary endpoint. 81% achieved clinical response at week 12, and 73.1% maintained it at 52 weeks. Lilly plans to submit these data to global regulators for potential label expansion. Omvoh is already approved for adult UC and Crohn's disease.

Eli Lilly (LLY) plans to expand Omvoh's use for pediatric ulcerative colitis after a successful late-stage trial. The company aims to seek an indication extension for the therapy, which is currently approved for bowel disease. This follows a one-year study showing positive results in children with the inflammatory colon condition.

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.

Eli Lilly announced that its late-stage trial for Omvoh in pediatric patients met the primary endpoint. The company's stock has seen a 6.59% increase year-to-date and a 16.97% increase over a longer period, according to the data provided.

Eli Lilly (LLY) reported positive Phase 3 trial results for Omvoh in pediatric ulcerative colitis, meeting its primary endpoint. 50% of patients achieved clinical remission at one year. The company plans to submit results to regulators for potential label expansion. LLY stock closed at $1257.03 on October 16, 2026, and was down 1.05% in pre-market trading.